Vyjuvek was approved in 2023, initially for patients at least six months of age, and could only be applied by healthcare professionals.

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Funded through a $17 million NIH grant, the program will try six strategies to combat HIV and advance the most promising.

The firm has voluntarily halted the SYNRGY study so it can investigate what caused the patient's death and will assess next steps based on the findings.

The agency said it will accept data from single-arm trials in its newly released Rare Disease Evidence Principles, but ...

Autonomous AI tools have great potential in supporting precision medicine, but developers are still figuring out how to deploy them in patient care.

Some feel the guidance may encourage consistent follow-up of overall survival after accelerated approvals, but others remain focused on speeding new drugs to patients.

NEW YORK – Hemogenyx Pharmaceuticals on Friday said it has treated the final patient with relapsed or refractory FLT3-expressing acute myeloid leukemia (AML) in the first dosing cohort of a Phase I ...

Phase II/III data showed that advanced gastric cancer patients on anbenitamab and chemotherapy fared better than those on standard therapy.

NEW YORK – Immunotherapy developer Xilio Therapeutics will showcase new masked T-cell engagers in its clinical pipeline over the next two years, the company said this week while announcing second ...

The firm will use the proceeds to fund clinical trials in thyroid eye disease, diabetes, geographic atrophy, and other chronic diseases.